Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Price:
109.29 USD
-0.92%
Market Closed
Updated:
May 3, 2024
Jazz Pharmaceuticals PLC
Net Income (Common)
|
Jazz Pharmaceuticals PLC
Net Income (Common) Peer Comparison
Comparables:
PRGO
AVDL
G
GHRS
COPN
OVB
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Net Income (Common)
$414.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Net Income (Common)
-$12.7m
|
CAGR 3-Years
57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Net Income (Common)
-$160.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-14%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Net Income (Common)
-$35.6m
|
CAGR 3-Years
-329%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Net Income (Common)
€1.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-34%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Net Income (Common)
-€2.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
10%
|
See Also
What is Jazz Pharmaceuticals PLC's Net Income (Common)?
Net Income (Common)
414.8m
USD
414.8m
USD
Based on the financial report for Dec 31, 2023, Jazz Pharmaceuticals PLC's Net Income (Common) amounts to 414.8m USD.
What is Jazz Pharmaceuticals PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
7%
7%
The average annual Net Income (Common) growth rates for Jazz Pharmaceuticals PLC have been 20% over the past three years , -1% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
